Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities

• Published in: Clinical interventions in aging Vol. 17; pp. 797 - 810
• Main Authors: Vaz, Miguel, Silva, Vítor, Monteiro, Cristina, Silvestre, Samuel
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 31.05.2022; Dove; Dove Medical Press
• Subjects: Alzheimer Disease - drug therapy; Alzheimer's disease; Amyloid beta-Peptides - metabolism; anti-aβ monoclonal antibody; Antibodies, Monoclonal, Humanized - therapeutic use; aria; Care and treatment; clinical trials; Diagnosis; european medicines agency; food and drug administration; Humans; Review; Risk factors; tau protein; United States; United States Food and Drug Administration; United States; anti-Aβ monoclonal antibody; clinical trials; European Medicines Agency; tau protein; Food and Drug Administration; ARIA
• ISSN: 1178-1998; 1176-9092; 1178-1998
• DOI: 10.2147/CIA.S325026

Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June 2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's disease (AD) approved by the US Food and Drug Administration (FDA), under the accelerated approval pathway. The decision was based on the ability of aducanumab to remove Aβ plaques, without any evidence that the Aβ clearance is correlated with less cognitive or functional decline. This decision has generated a considerable debate in the scientific community, especially because the results from the two Phase 3 trials, EMERGE and ENGAGE, were divergent and, even after the post hoc analysis, the data were insufficient to prove aducanumab efficacy. Moreover, some researchers think that this approval will be an obstacle to the progress and also demonstrated concerns about aducanumab cost and its safety profile. The European Medicines Agency's rejection of aducanumab in December 2021 just brought more controversy over FDA's decision. Now, Biogen is designing the FDA's required confirmatory study, named ENVISION, which should be complete in 2026. Despite the controversy, the aducanumab showed to affect downstream tau pathology, which could open doors for a combination therapy approach for AD (anti-tau and anti-amyloid drug). This review summarizes the clinical development of aducanumab until regulatory agencies' decisions, the available trials data and the controversy over aducanumab approval for AD.